COYA

Coya Therapeutics, Inc. (COYA) | Rumor.io

Coya Therapeutics

COYA

Attention (50-day avg)0%

Attention rank (50-day avg)#2,143

Bullish sentiment (50-day avg)96%

Price to earnings ratio-3.93

Market capitalization116.8M

Earnings per share-1.07

Dividend yield (TTM)—

Revenue (annual)7.9M

Net income (annual)-21.2M

Social

What share of all stock conversation is about COYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 24

Coya Therapeutics, Inc. (COYA) is developing a treatment for ALS and FTD by targeting T regulatory cells to fight neuroinflammation, with the ALSTARS trial progressing and FDA Fast Track designation.
The company's asset is expected to be worth billions of dollars if the Q1 readout for ALS is successful, and the proteomics data in Nov/Dec will provide further validation of the science and potential licensing deals/partnerships.
Leerink is expected to issue an outperform rating and $12 target for COYA, with a potential M&A opportunity in the sweet spot, and the company is poised to make significant progress with the ENCALS conference.

Generated by AI

Sentiment

Of the messages about COYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +37.5	91.49% -8.51	94.2% -1.08
Bearish	0%	0% -37.5	8.51% +8.51	5.8% +1.08

Bullish· Jul 17

$COYA is expected to reach $5.00 and beyond in the near future, with a bright future ahead.
Breaking through $4.50 will trigger a significant price increase, potentially reaching $5.50 or more.
With a low float and increasing buying pressure, $COYA has the potential to spike to $10 or higher.

Bearish· May 16

$COYA's high volatility and frequent halts suggest a manipulated market.
The asset's low float may contribute to violent price movements and a lack of available shares for shorting.
The shorts' control over the market and the asset's failure to break out indicate a bearish sentiment.

Generated by AI

Topics

Of the messages about COYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	57.14%	15.68%
Announcements	—	50%	14.29%	74.59%
Technical Analysis	—	50%	28.57%	8.09%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.17%
Macro	—	0%	0%	1.49%

Aug 25

Coya Therapeutics' IND application for COYA 302, a treatment for ALS, has been accepted by the FDA, clearing the way for a Phase 2 trial.
The FDA acceptance triggers a $4.2 million milestone payment from partner Dr. Reddy's, reinforcing the strategic partnership between the two companies.
The approval is seen as a significant step forward in the development of a treatment for ALS, with investors highlighting the potential of COYA 302 and the strength of the partnership between Coya Therapeutics and Dr. Reddy's.

Generated by AI

Community

Of the messages about COYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75%	84.48%	87.5%	75.36%
Newcomers	25%	15.52%	12.5%	24.64%

Jul 17

Newcomers are focused on Coya Therapeutics' ($COYA) positive clinical trial data for Alzheimer's disease, with one post highlighting the company's proof-of-concept biomarker data.
Some newcomers are comparing COYA's performance to that of Abos (ABOS), another Alzheimer's-focused stock, and believe COYA's momentum will surpass ABOS' gains.
New investors are optimistic about COYA's potential for double-digit growth, with one post predicting a price target of $5.70, citing the stock's low float as a key factor.

Generated by AI

HOUSTON, September 08, 2026--Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today announced the publication of preclinical results for COYA 303 in the International Journal of Molecular Sciences. The article was published as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic app

21d agoYahoo! Finance Canada

Wall Street Analysts Are Bullish on Top Healthcare Picks

Detailed price information for Medtronic Inc (MDT-N) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

H.C. Wainwright reiterates Coya Therapeutics stock rating at buy

1mo agoInvesting.com

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

Detailed price information for Palisade Bio Inc (PALI-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about COYA also mention

#	Name	Attention
1	Gain Therapeutics, Inc.GANX	0.04%+0.02
2	INmune Bio Inc.INMB	0%0
3	PolyPid Ltd.PYPD	0%new
4	BCLI - Brainstorm Cell Therapeutics Inc.	——
5	BioVie Inc.BIVI	0%0
6	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
7	WRNT - Warrantee Inc. American Depositary Shares	——
8	Annovis Bio, Inc.ANVS	0%0
9	PRVB - Provention Bio, Inc.	——
10	Gossamer Bio Inc.GOSS	0%+0

Coya Therapeutics, Inc.

Healthcare
Biotechnology

Coya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies that enhance the function of regulatory T cells, or Tregs. The company’s current pipeline centers on multiple immune-modulating approaches, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. These programs are designed to address systemic inflammation and neuroinflammation across serious conditions such as neurodegenerative, autoimmune, chronic inflammatory, and metabolic diseases. Coya Therapeutics is particularly active in advancing treatments intended to restore immune balance and support disease-modifying approaches in areas with significant unmet medical need. Based in Houston, Texas, Coya Therapeutics operates within the broader healthcare and biotechnology markets, where its platform-based strategy positions it as a developer of specialized immunotherapy candidates.

Website

Location

5850 San Felipe St.

Houston, TX, 77057

United States

Social

What share of all stock conversation is about COYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% 0	0% 0

Jun 24

Coya Therapeutics, Inc. (COYA) is developing a treatment for ALS and FTD by targeting T regulatory cells to fight neuroinflammation, with the ALSTARS trial progressing and FDA Fast Track designation.
The company's asset is expected to be worth billions of dollars if the Q1 readout for ALS is successful, and the proteomics data in Nov/Dec will provide further validation of the science and potential licensing deals/partnerships.
Leerink is expected to issue an outperform rating and $12 target for COYA, with a potential M&A opportunity in the sweet spot, and the company is poised to make significant progress with the ENCALS conference.

Generated by AI

Sentiment

Of the messages about COYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100% +37.5	91.49% -8.51	94.2% -1.08
Bearish	0%	0% -37.5	8.51% +8.51	5.8% +1.08

Bullish· Jul 17

$COYA is expected to reach $5.00 and beyond in the near future, with a bright future ahead.
Breaking through $4.50 will trigger a significant price increase, potentially reaching $5.50 or more.
With a low float and increasing buying pressure, $COYA has the potential to spike to $10 or higher.

Bearish· May 16

$COYA's high volatility and frequent halts suggest a manipulated market.
The asset's low float may contribute to violent price movements and a lack of available shares for shorting.
The shorts' control over the market and the asset's failure to break out indicate a bearish sentiment.

Generated by AI

Topics

Of the messages about COYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	57.14%	15.68%
Announcements	—	50%	14.29%	74.59%
Technical Analysis	—	50%	28.57%	8.09%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0.17%
Macro	—	0%	0%	1.49%

Aug 25

Coya Therapeutics' IND application for COYA 302, a treatment for ALS, has been accepted by the FDA, clearing the way for a Phase 2 trial.
The FDA acceptance triggers a $4.2 million milestone payment from partner Dr. Reddy's, reinforcing the strategic partnership between the two companies.
The approval is seen as a significant step forward in the development of a treatment for ALS, with investors highlighting the potential of COYA 302 and the strength of the partnership between Coya Therapeutics and Dr. Reddy's.

Generated by AI

Community

Of the messages about COYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	75%	84.48%	87.5%	75.36%
Newcomers	25%	15.52%	12.5%	24.64%

Jul 17

Newcomers are focused on Coya Therapeutics' ($COYA) positive clinical trial data for Alzheimer's disease, with one post highlighting the company's proof-of-concept biomarker data.
Some newcomers are comparing COYA's performance to that of Abos (ABOS), another Alzheimer's-focused stock, and believe COYA's momentum will surpass ABOS' gains.
New investors are optimistic about COYA's potential for double-digit growth, with one post predicting a price target of $5.70, citing the stock's low float as a key factor.

Generated by AI

Coya Therapeutics

Social

Jun 24

Sentiment

Bullish· Jul 17

Bearish· May 16

Topics

Aug 25

Community

Jul 17

News

Exosomes Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 100+ Leading Players Wheeling the Therapeutics Landscape

Coya Therapeutics stock maintained at Buy by H.C. Wainwright

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

Wall Street Analysts Are Bullish on Top Healthcare Picks

H.C. Wainwright reiterates Coya Therapeutics stock rating at buy

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

Also Discussed

Coya Therapeutics, Inc.

Company Information

Location

News

Exosomes Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 100+ Leading Players Wheeling the Therapeutics Landscape

Coya Therapeutics stock maintained at Buy by H.C. Wainwright

Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation

Wall Street Analysts Are Bullish on Top Healthcare Picks

H.C. Wainwright reiterates Coya Therapeutics stock rating at buy

Analysts Are Bullish on Top Healthcare Stocks: Coya Therapeutics, Inc. (COYA), Palisade Bio (PALI)

Also Discussed

Social

Jun 24

Sentiment

Bullish· Jul 17

Bearish· May 16

Topics

Aug 25

Community

Jul 17